PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
Stopped "Company is in a process of being taken over by another pharma and the new one has different ideas on how to pursue studies with this drug"
Conditions
- Myelofibrosis Transformation in Essential Thrombocythemia
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
- Primary Myelofibrosis
Interventions
- DRUG: LOXL2 Inhibitor PAT-1251
- OTHER: Quality-of-Life Assessment
- OTHER: Questionnaire Administration
Sponsor
M.D. Anderson Cancer Center
Collaborators